JP2022551911A - 遺伝子治療の心外膜送達 - Google Patents

遺伝子治療の心外膜送達 Download PDF

Info

Publication number
JP2022551911A
JP2022551911A JP2022521637A JP2022521637A JP2022551911A JP 2022551911 A JP2022551911 A JP 2022551911A JP 2022521637 A JP2022521637 A JP 2022521637A JP 2022521637 A JP2022521637 A JP 2022521637A JP 2022551911 A JP2022551911 A JP 2022551911A
Authority
JP
Japan
Prior art keywords
subject
heart
vegf
injection
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551911A5 (https=
Inventor
リッキー ラインハート
トッド ローゼンガート
ロナルド クリスタル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2022551911A publication Critical patent/JP2022551911A/ja
Publication of JP2022551911A5 publication Critical patent/JP2022551911A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022521637A 2019-10-09 2020-10-09 遺伝子治療の心外膜送達 Pending JP2022551911A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912958P 2019-10-09 2019-10-09
US62/912,958 2019-10-09
PCT/US2020/055082 WO2021072272A1 (en) 2019-10-09 2020-10-09 Epicardial delivery of gene therapy

Publications (2)

Publication Number Publication Date
JP2022551911A true JP2022551911A (ja) 2022-12-14
JP2022551911A5 JP2022551911A5 (https=) 2023-10-17

Family

ID=75437778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521637A Pending JP2022551911A (ja) 2019-10-09 2020-10-09 遺伝子治療の心外膜送達

Country Status (6)

Country Link
US (1) US20240115732A1 (https=)
EP (1) EP4041192A4 (https=)
JP (1) JP2022551911A (https=)
CN (1) CN115151262A (https=)
CA (1) CA3153845A1 (https=)
WO (1) WO2021072272A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233783A1 (en) * 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514929A (ja) * 2002-11-15 2006-05-18 ジェンベク、インコーポレイティッド 冠動脈疾患の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU745409B2 (en) * 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
US6197324B1 (en) * 1997-12-18 2001-03-06 C. R. Bard, Inc. System and methods for local delivery of an agent
US20060084622A1 (en) * 1998-03-11 2006-04-20 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US7288521B2 (en) * 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
EP3329779B1 (en) * 2012-11-02 2019-06-05 Cornell University Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium
EP2925863B1 (en) * 2012-11-30 2020-07-15 Vestion Inc. Cardiac stem cells and methods of identifying and using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514929A (ja) * 2002-11-15 2006-05-18 ジェンベク、インコーポレイティッド 冠動脈疾患の治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOL. THER., vol. 12, [4], JPN6024029811, 2005, pages 716 - 724, ISSN: 0005537463 *

Also Published As

Publication number Publication date
WO2021072272A1 (en) 2021-04-15
US20240115732A1 (en) 2024-04-11
EP4041192A1 (en) 2022-08-17
EP4041192A4 (en) 2023-11-08
CA3153845A1 (en) 2021-04-15
CN115151262A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
Grines et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina
Perin et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase–bright stem cells in patients with ischemic heart failure
DE69827021T2 (de) An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
Sarkar et al. Effects of intramyocardial injection of phVEGF‐A165 as sole therapy in patients with refractory coronary artery disease–12‐month follow‐up: angiogenic gene therapy
Favaloro et al. High‐dose plasmid‐mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis‐I). A phase I, open‐label, two‐year follow‐up trial
Ling et al. Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation
Gwizdala et al. Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure
Perrault et al. Sequential multidetector computed tomography assessments after venous graft treatment solution in coronary artery bypass grafting
JP2010053144A (ja) 血管形成的に有効なｆｇｆ−２の単位用量および使用方法
Yu et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction
Yokokawa et al. The course of the sinus node artery and its impact on achieving linear block at the left atrial roof in patients with persistent atrial fibrillation
Sylvén et al. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris
Zhao et al. Defective endothelial glutaminolysis contributes to impaired angiogenesis and poor ischemic tissue repair in diabetes
JP2022551911A (ja) 遺伝子治療の心外膜送達
Zhu et al. Myocardial microvascular function during acute coronary artery stenosis: effect of hypertension and hypercholesterolaemia
Kalil et al. VEGF gene therapy for angiogenesis in refractory angina: phase I/II clinical trial
Laufs et al. Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association
US20050191278A1 (en) Coronary artery disease treatment
Ahmed et al. Off-pump combined coronary artery bypass grafting and left upper lobectomy through left posterolateral thoracotomy
Luo et al. Efficacy of vein of Marshall ethanol infusion added to left atrial anatomical ablation for treatment of persistent atrial fibrillation in patients with hypertrophic cardiomyopathy
Stegmann et al. Therapeutic angiogenesis: intramyocardial growth factor delivery of FGF-1 as sole therapy in patients with chronic coronary artery disease
Zhang et al. In-hospital outcomes of Revascularization in patients with left ventricular systolic dysfunction and coronary chronic total occlusion
Pokushalov et al. Cardiac resynchronization therapy and bone marrow cell transplantation in patients with ischemic heart failure and electromechanical dyssynchrony: a randomized pilot study
Balik et al. M. Balik1*, T. Tencer2, E. Svobodova1, M. Otahal1, I. Jurisinova1, V. Kaspar1, A. Krajcova3, F. Duska3 and P. Waldauf3
Zhao et al. Salvianolic acid B, a novel GLS1 accelerator, alleviates defective endothelial glutaminolysis contributes to impaired angiogenesis and poor ischemic tissue repair in diabetes

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250227